Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at WallStreetSectors.com, will continue to monitor these healthtech companies to see if the momentum continues. WallStreetSectors.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent EDIT Stock Price: $10.95
Summary: Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.
Matthew Harrison analyst at Morgan Stanley reiterates coverage on Editas Medicine (EDIT) stock in the energy sector with a Sell rating and has set EDIT's stock price target at $ 8.
TipRanks.com reports that Editas Medicine currently has 13 analysts offering 12-month price targets on EDIT and the consensus is a Hold rating with an average stock price target of $15.15. The most recent EDIT stock price we have is $10.95 and we are not making any EDIT forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for EDIT over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on EDIT. WallStreetSectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on EDIT, please click here >>
Iovance Biotherapeutics, IOVA
Recent IOVA Stock Price: $6.62
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
Geulah Livshits analyst at Chardan Capital reiterates coverage on Iovance Biotherapeutics (IOVA) stock in the energy sector with a Buy rating and has set IOVA's stock price target at $ 29.
TipRanks.com reports that Iovance Biotherapeutics currently has 8 analysts offering 12-month price targets on IOVA and the consensus is a Strong Buy rating with an average stock price target of $26.86. The most recent IOVA stock price we have is $6.62 and we are not making any IOVA forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for IOVA over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA. WallStreetSectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on IOVA, please click here >>
EDAP TMS, EDAP
Recent EDAP Stock Price: $9.95
Summary: EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors.
Frank Takkinen analyst at Lake Street reiterates coverage on EDAP TMS (EDAP) stock in the energy sector with a Buy rating and has set EDAP's stock price target at $ 14.
TipRanks.com reports that EDAP TMS currently has 4 analysts offering 12-month price targets on EDAP and the consensus is a Strong Buy rating with an average stock price target of $12.25. The most recent EDAP stock price we have is $9.95 and we are not making any EDAP forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for EDAP over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on EDAP. WallStreetSectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on EDAP, please click here >>
Viewray, VRAY
Recent VRAY Stock Price: $4.62
Summary: ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio.
Cecilia Furlong analyst at Morgan Stanley reiterates coverage on Viewray (VRAY) stock in the energy sector with a Hold rating and has set VRAY's stock price target at $ 5.5.
TipRanks.com reports that Viewray currently has 5 analysts offering 12-month price targets on VRAY and the consensus is a Strong Buy rating with an average stock price target of $6.80. The most recent VRAY stock price we have is $4.62 and we are not making any VRAY forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for VRAY over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on VRAY. WallStreetSectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on VRAY, please click here >>
Apellis Pharmaceuticals, APLS
Recent APLS Stock Price: $50.45
Summary: Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
Phil Nadeau analyst at Cowen & Co. reiterates coverage on Apellis Pharmaceuticals (APLS) stock in the energy sector with a Buy rating and has set APLS's stock price target at $ 70.
TipRanks.com reports that Apellis Pharmaceuticals currently has 14 analysts offering 12-month price targets on APLS and the consensus is a Strong Buy rating with an average stock price target of $76.14. The most recent APLS stock price we have is $50.45 and we are not making any APLS forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for APLS over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on APLS. WallStreetSectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on APLS, please click here >>
The editors at WallStreetSectors.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
WallStreetSectors.com keeps investors investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to WallStreetSectors.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================